DCPH News and Press, Deciphera Pharmaceuticals Inc. From 02/14/20

Pulse Biosciences (NASDAQ: PLSE )  -44%  after disclosing NSE letter from FDA on CellFX system. More news on: Pulse Biosciences, Inc., CarGurus, Inc., LivePerson, Inc., Stocks on the move, , Read more ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) has priced its public offering of ~3.2M common shares at $55.00 per share. Underwriters' over-allotment is an additional ~477K shares. Closing date is February 19. More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on t...

Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. The pre-revenue pharmaceutical company intends to raise gross proceeds of up to $287.5 million, although the number of shares offered won't b...

- FDA Grants Priority Review and sets PDUFA Date of August 13, 2020 - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the ...

Blueprint's (Most Recent) Raise Closed: TBD (proposed pricing on 1/22/20) Pricing: $69.00/share Amount: ~$325 million Over-allotment: TBD Blueprint Medicines ( BPMC ) recently announced a dilutive raise, sending share prices below key moving averages: Blueprint's la...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...

- Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program - - Commercial Preparations Underway to Support Potential Approval and Launch of ...

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...